MELBOURNE, Australia and NEW YORK, April 12, 2015 -- Mesoblast Limited today announced that the Company has entered into an Agreement with US-based Celgene Corporation, a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Pursuant to this Agreement, Celgene will purchase Mesoblast stock and has a six-month right of first refusal to certain disease fields.
http://www.globenewswire.com/news-release/2015/04/13/723565/10128531/en/Celgene-And-Mesoblast-Enter-Into-Equity-Placement-and-Right-of-First-Refusal-Agreement-To-Certain-Disease-Fields.html
http://www.globenewswire.com/news-release/2015/04/13/723565/10128531/en/Celgene-And-Mesoblast-Enter-Into-Equity-Placement-and-Right-of-First-Refusal-Agreement-To-Certain-Disease-Fields.html
No comments:
Post a Comment